StockIQpro
NASDAQ:ATOS

Atossa Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Atossa Therapeutics, Inc. reported net income of −$34.8M in fiscal 2025. Free cash flow was −$29.8M, and the diluted share count rose 2.6%.Summary generated from Atossa Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 25, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−62.7%
Debt / equityn/a
Free cash flow−$29.8M
FCF marginn/a
Share count change+2.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−21−28−31−28−37
Net income−21−27−30−26−35
Free cash flow−16−21−21−21−30

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations